Clinical trial

Investigating the Efficacy of Short-term Oral Prednisone Therapy on Acute Subjective Tinnitus

Name
STOP for AST
Description
The goal of this clinical trial is to investigate the efficacy of oral steroids in the acute tinnitus population. Participants will receive appropriate dosages of short-term prednisone and/or oral Ginkgo Biloba tablets.
Trial arms
Trial start
2022-10-30
Estimated PCD
2023-01-22
Trial end
2024-02-03
Status
Completed
Treatment
Prednisone tablet
The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
Arms:
STOP group
Other names:
prednisone
Ginkgo Biloba Extract
Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
Arms:
STOP group, placebol group
Other names:
ginkgo biloba
Size
146
Primary endpoint
tinnitus handicap inventory (THI)
two weeks from baseline
tinnitus handicap inventory (THI)
four weeks from baseline
tinnitus handicap inventory (THI)
twelve weeks from baseline
Eligibility criteria
Inclusion Criteria: 1. 18-65 years old; 2. a primary complaint of frequent occurrences of subjective tinnitus lasting at least 5 minutes within the past 3 months ; 3. a definition of normal hearing in line with the World Report on Hearing (2021), of which the average value of hearing threshold at 500, 1000, 2000, 4000 Hz in better ear was less than 20 decibels; 4. a score of more than 16 points on the Tinnitus Handicap Inventory (THI), which indicates that the level of tinnitus exceeds mild severity; 5. a state of good general condition. Exclusion Criteria: 1. had previous history of middle ear pathology, apparent history of noise exposure, noise trauma or head injury; 2. had received treatment for their current condition before the study; 3. taken oral steroids within 3 months before randomization; 4. had hearing implants; 5. had participated in other clinical trials and have not terminated the trials; 6. had a history of known corticosteroid contraindications (including osteoporosis, peptic ulcers, poorly controlled hypertension, diabetes, chronic liver or renal insufficiency, tumorous condition, alcohol abuse, pregnancy, or taking estrogen-containing oral contraceptive steroids); 7. auditory hallucinations or other conditions deemed inappropriate for inclusion by the investigator.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 146, 'type': 'ACTUAL'}}
Updated at
2024-05-29

1 organization

2 products

2 indications

Product
Prednisone
Indication
Tinnitus
Indication
Subjective